Crown Laboratories to Acquire Revance Therapeutics in $924 Million Merger

In a move that could reshape the landscape of the aesthetics and skincare industry, Crown Laboratories, Inc. announced its agreement to acquire Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company specializing in neuromodulators and innovative aesthetic solutions. The merger, valued at approximately $924 million, will result in the formation of a new combined entity, significantly expanding Crown’s footprint in the global skincare market.

Under the terms of the agreement, Crown will acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash. The transaction, which is expected to close by the end of 2024, will see Revance becoming a wholly owned subsidiary of Crown. Following the merger, Revance’s shares will cease to be publicly traded on the Nasdaq.

“This is a significant step forward in Crown’s vision to become a fully integrated global aesthetics and skincare company, bringing innovative solutions to physicians, patients, and consumers in the incredibly dynamic aesthetics and skincare market,” said Jeff Bedard, Crown’s founder and CEO, in a statement.

The merger represents a strategic alignment between Crown, a private company known for its broad portfolio of skincare products, and Revance, a biotechnology firm recognized for its advancements in neuromodulators, including its flagship product, DaxibotulinumtoxinA, an injectable neuromodulator for aesthetic and therapeutic use.

By combining forces, Crown and Revance aim to leverage their respective strengths in product development, marketing, and distribution, creating a powerhouse in the aesthetics and skincare sectors. The merger is expected to enhance Crown’s capabilities in providing innovative, science-driven solutions to a global customer base, positioning the company for accelerated growth in an increasingly competitive market.

The transaction is subject to regulatory approvals and customary closing conditions. Once completed, the merger will mark a significant milestone in Crown’s journey toward becoming a leading global player in the aesthetics and skincare industry.

For Revance, the acquisition provides an opportunity to expand its reach and resources under the umbrella of Crown, while also offering shareholders a substantial premium on their investments.

As the year progresses, the industry will be watching closely to see how this merger influences the competitive dynamics within the aesthetics and skincare market. With the integration of Revance’s innovative technologies and Crown’s established market presence, the new combined company is poised to make a significant impact on the future of beauty and wellness.

Financial Desk